Novo Nordisk AS Newswire

Comprehensive Real-Time News Feed for Novo Nordisk AS.

Results 1 - 20 of 462 in Novo Nordisk AS

  1. Are Sellers Wrong to Be Short MannKind Corp.?Read the original story w/Photo

    Friday | The Motley Fool

    Those bearish bets reflect expectations that Afrezza's sales will be tepid; however, short-sellers may end up discovering that they've taken on too much risk. A big and changing market Insulin is used to regulate diabetes, and the number of cases of diabetes globally is expected to surge.

    Comment?

  2. Biophysicist receives EliteForsk Award 2015Read the original story w/Photo

    Wednesday Feb 25 | EurekAlert!

    Eliteforsk award Biophysics professor Lene Oddershede of the University of Copenhagen's Niels Bohr Institute at the Faculty of Science will receive an EliteForsk Award - Denmark's largest public research award - on Thursday, February 26. Lene Oddershede's work mainly focuses on an interdisciplinary research domain where physics, biology and medicine merge. Among other things, award funding will go to build new equipment that will be used to better understand how the development of stem cells can be steered for the benefit of patients worldwide.

    Comment?

  3. Mapping lizard venom makes it possible to develop new drugsRead the original story

    Thursday Feb 26 | Medical News Today

    Gila and beaded lizards are the classic venomous lizards. However, it was recently shown that venom is also used by a number of other species, such as the awesome Komodo monitors - the largest present-day lizards.

    Comment?

  4. Novo Nordisk rider Ruud Cremers hospitalized with head injuryRead the original story w/Photo

    Wednesday Feb 25 | Velonews

    Ruud Cremers sustained a head injury Monday after crashing hard during the Vuelta Independencia Nacional in the Dominican Republic. According to a team release, Cremers went down during stage 2 of the eight-day race.

    Comment?

  5. UPDATE 1-Novo Nordisk has positive trial results for oral diabetes drug, shares jumpRead the original story

    Tuesday Feb 24 | Reuters

    Danish drugmaker Novo Nordisk , the world's biggest insulin maker, said on Friday it had received positive results from a Phase II trial of an oral version of a long-acting GLP-1 drug for treatment of people with type 2 diabetes. The process could take a year or more to complete, but promises to bring forward the treatment of diabetes by pills rather than injections, long considered an important step for the Danish company as well as for diabetes sufferers.

    Comment?

  6. Novo Nordisk has positive trial results for oral GLP-1 drug, shares jumpRead the original story

    Tuesday Feb 24 | Reuters

    Danish drugmaker Novo Nordisk , the world's biggest insulin maker, said on Friday it had received positive results from a phase 2 trial of an oral version of a long-acting GLP-1 for treatment of people with type 2 diabetes. GLP-1 drugs work by stimulating the release of insulin when blood-sugar levels become too high.

    Comment?

  7. Positive Results Reported for Oral Semaglutide in Diabetes PatientsRead the original story

    Monday Feb 23 | P&T Community

    Positive results have been reported from a phase II study of OG217SC , an oral formulation of the long-acting glucagon-like peptide-1 analogue semaglutide, compared with placebo or subcutaneous semaglutide in approximately 600 subjects with type-2 diabetes. The trial investigated clinical efficacy and safety, along with the dosing range and dose escalation, in subjects receiving once-daily oral semaglutide, once-daily oral placebo, or once-weekly SC semaglutide for 26 weeks.

    Comment?

  8. Diabetes educator to speakRead the original story

    Monday Feb 23 | WVII

    Sebasticook Valley Health announces that diabetes educator Amanda Poulin, RD, LD, from Novo Nordisk will be the featured speaker at the March 12th SVH Diabetes Support Group meeting . Ms. Poulin will provide information about diabetes medications.

    Comment?

  9. Capturing The Growth Of The Diabetic Epidemic Via Shares Of Novo NordiskRead the original story w/Photo

    Monday Feb 23 | Seeking Alpha

    As the worlds population continues to age and become more sedentary, I expect the in incidence of diabetes to expand. Diabetes remains one of the deadliest afflictions known to mankind.

    Comment?

  10. China Biologic Products Q4 2014 Earnings: Primed For A Sell-Off?Read the original story w/Photo

    Monday Feb 23 | Seeking Alpha

    The stock has risen to record highs since my initial report. Shares traded around $80 earlier in the week, up 47% from when my SA article was published last year.

    Comment?

  11. Novo Nordisk to raise up to $335 million from IT subsidiary's IPORead the original story

    Monday Feb 23 | Reuters

    NNIT, which provides IT services to its parent and other companies, set an indicative price for the public offer of 40 percent of the company, at 100 to 120 crowns a share. Based on the price range and assuming full exercise of an overallotment option amounting to a further 6 percent of the share capital, proceeds are expected to be 1.863 billion to 2.235 billion crowns, valuing NNIT at 2.5 to 3 billion crowns.

    Comment?

  12. Novo Nordisk A/S - Share repurchase programmeRead the original story

    Monday Feb 23 | PR-inside.com

    Bagsvaerd, Denmark, 23 February 2015 - On 30 January 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2015.

    Comment?

  13. Drug delivery tech's shares skyrocket as it helps Novo Nordisk clear Phase II hurdleRead the original story w/Photo

    Monday Feb 23 | In-PharmaTechnologist.com

    A potential Type 2 diabetes drug from Novo Nordisk has met the primary endpoint of a Phase II trial and shares of Emisphere Technology, which helped to formulate the oral version of semaglutide, jumped by as much as 70% on Friday. The potential treatment, semaglutide, which is a long-acting human GLP-1 analogue that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner, is being developed for once-weekly subcutaneous use and for once-daily oral administration for the treatment of type 2 diabetes.

    Comment?

  14. Nnit a/S: Company announcement 1/2015 S borg/Copenhagen, 23 February 2015Read the original story

    Sunday Feb 22 | GlobeNewswire

    NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This is an announcement and does not constitute an offering circular. The offer to acquire securities pursuant to the offering is made, and any investor should make his or her investment decision, solely on the basis of information in the offering circular made generally available in Denmark in connection with the offering.

    Comment?

  15. Emisphere Technologies, Inc. Highlights Positive Phase 2 Og217sc Data ...Read the original story

    Sunday Feb 22 | BioSpace

    Emisphere Technologies, Inc. today highlighted positive Phase 2 data from EligenA licensee Novo Nordisk pertaining to OG217SC, the oral formulation of semaglutide, a long-acting human GLP-1 analogue that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. OG217SC is provided in a tablet formulation with an absorption-enhancing excipient, SNAC.

    Comment?

  16. Novo Nordisk finishes study of oral diabetes drugRead the original story w/Photo

    Friday Feb 20 | Seeking Alpha

    Novo Nordisk completes a 600-subject Phase 2 trial comparing an oral formulation of the long-acting GLP-1 analogue , semaglutide, to once-weekly semaglutide injections and oral placebo in patients with type 2 diabetes. From a mean baseline HbA1c of 7.9%, patients treated with five different doses of oral semaglutide achieved dose-dependent improvements in HbA1c of 0.7% to 1.9% after 26 weeks.

    Comment?

  17. European shares touch multi-year highs, DAX sets new recordRead the original story

    Friday Feb 20 | Reuters

    European stock markets touched new multi-year highs on Friday, with the German market near record levels, as euro zone finance ministers prepared another attempt at reaching a deal on Greece. Germany's DAX closed up 0.4 percent at 11,050.64 points - its highest ever closing level and near a record intraday peak of 11,081.81 points set earlier in the day.

    Comment?

  18. Novo Nordisk Pops On Successful Diabetes Drug TrialRead the original story w/Photo

    Friday Feb 20 | Investor's Business Daily

    The drug, called OG217SC, is used for type 2 diabetes. It is an oral version of Novo's semaglutide, a once-weekly GLP-1 analogue.

    Comment?

  19. UPDATE 1-Novo Nordisk has positive trial results for oral diabetes drug, shares jumpRead the original story

    Friday Feb 20 | Reuters

    Danish drugmaker Novo Nordisk , the world's biggest insulin maker, said on Friday it had received positive results from a Phase II trial of an oral version of a long-acting GLP-1 drug for treatment of people with type 2 diabetes. The process could take a year or more to complete, but promises to bring forward the treatment of diabetes by pills rather than injections, long considered an important step for the Danish company as well as for diabetes sufferers.

    Comment?

  20. Novo Nordisk has positive trial results for oral GLP-1 drug, shares jumpRead the original story

    Friday Feb 20 | WNFL-AM Green Bay

    Danish drugmaker Novo Nordisk, the world's biggest insulin maker, said on Friday it had received positive results from a phase 2 trial of an oral version of a long-acting GLP-1 for treatment of people with type 2 diabetes. GLP-1 drugs work by stimulating the release of insulin when blood-sugar levels become too low.

    Comment?